SOSamih Abed Odhaib

Samih Abed Odhaib

*This is an algorithmically generated author record based on publicly available information.

Samih Abed Odhaib has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thyroid nodules stratification by American Thyroid Association and American College of Radiology lexicons: Thi-qar study

    by Dheyaa Kadhim Al-Waeli, Adel Gassab Mohammed, Samih Abed Odhaib, Mahmood Thamer Altemimi, Shakir Aglah Khalifa, Israa Ali Hasan, Mohammed Uday Hatim, Imad Hatim Tahir

    The diagnostic performance of sonography to manage thyroid nodule (TN) may influence excess biopsy in different clinical settings. American College of Radiology (ACR) presented Thyroid Imaging Reporting and Data Systems (TIRADS) lator to American Thyroid Association (ATA) risk stratification guidelines, with variable diagnostic performance. The objective of this study is to evaluate the effectiveness of ACR-TIRADS versus ATA lexicons for thyroid cancer prediction among individuals with TN in Thi-Qar, Iraq. This cross-sectional observational study enrolled 1,007 individuals aged ≥ 14 years with 1,155 TNs attending a tertiary endocrine center. Malignancy risk was classified using both ACR-TIRADS and ATA lexicons with matched categories: TIRAD-1 (Benign<1%), TIRAD-2 (Very Low<3%), (TIRAD-3 (Low 5-10%), (TIRAD-4 (Intermediate 10-20%), and (TIRAD-5 (High 70-90%). Fine needle aspiration (FNAC) and histopathological diagnosis were made according to the Bethesda system and agreement between lexicons was assessed using sensitivity, specificity, Cohen’s Kappa Statistics, and McNemar test. Among participants, 85.2% were women, with mean age 46±14 years. Most individuals were euthyroid (71%), TNs were located in right lobe (51.3%), left lobe (42.5%), and isthmus (6.1%). FNAC was indicated for 54.6% of TNs by ATA and 44.6% by ACR-TIRADS criteria. High-risk cytology (Bethesda IV-V) was 7.1% and ATA system demonstrated higher sensitivity (74.3%) and accuracy (58.6%) than ACR-TIRADS (sensitivity 60%, accuracy 53%), though both gave modest diagnostic performance and low positive predictive values (<12%). Agreement between systems was weak (Cohen’s κ=0.265±0.032, p < 0.001), with concordance in 50.1% of cases. Both risk stratification systems had comparable but modest diagnostic performance. ATA identified more FNAC-eligible TNs with slightly higher sensitivity, specificity, prediction, and overall accuracy. However, the weak agreement between raters highlights variability in nodule categorization and management, supporting the need to integrate sonographic findings with clinical and biochemical factors to optimize TNs evaluation and minimize unnecessary biopsies.


  • Quality of Life in Polycystic Ovary Syndrome after Anti-Androgen Therapy Using PCOSQOL-47 and PCOSQOL-42

    by Samih Abed Odhaib, Mahmood Thamer Altemimi, Adel Gassab Mohammed, Dheyaa Kadhim Al-Waeli, Miaad Jassim Mohammed, Haider Ayad Alidrisi, Husam Jihad Imran, Abbas Ali Mansour

    Introduction: Hyperandrogenism in Polycystic ovary syndrome (PCOS) negatively affects health-related quality of life (HRQOL). Anti-androgens may improve both biochemical and patient-related outcomes. Objectives: To evaluate the impact of combined finasteride and spironolactone on HRQOL in married and unmarried women with PCOS using PCOSQOL-47 and PCOSQOL-42, respectively. Methods: A total of 263 married and 236 unmarried women with PCOS were enrolled from two tertiary centers. All received finasteride (5mg) and spironolactone (100mg) daily and were followed every four months over a year. HRQOL was assessed using PCOSQOL-47 for married and PCOSQOL-42 for unmarried women, alongside evaluating their biochemical and clinical hyperandrogenism. Results: After one year, significant reductions were observed in total and free testosterone, dehydroepiandrosterone sulfate, body mass index (BMI), and a decrease in modified Ferriman-Gallwey (mFG) scores. Both groups showed marked HRQOL improvement, greater in unmarried women. In PCOSQOL-47, psychological and emotional domains improved most, while fertility and sexual domains improved least. In PCOSQOL-42, menstrual and fertility domains had the highest gains, while coping improved least. Both groups had a 25% reduction in mFG score and 5% reduction in BMI. Discussion: This is the first study to evaluate combined finasteride and spironolactone on HRQOL domains in PCOS using PCOSQOL-47 and PCOSQOL-42. Prior studies assessing anti- androgens used other tools, without distinction between married and unmarried women. Conclusions: Combined finasteride and spironolactone significantly improved all HRQOL scales and reduced hyperandrogenism within the first four months in women with PCOS, supporting its role alongside lifestyle measures.

  • Open Access

    Sexual dysfunction in women with newly diagnosed thyroid dysfunction: a novel report from Basrah, Iraq

    by Samih Abed Odhaib, Mahmood Thamer Altemimi, Abbas Ali Mansour

    Thyroid dysfunction has been proposed as a potential contributor to Female Sexual Dysfunction (FSD), yet its impact, particularly in subclinical and autoimmune forms, remains controversial, especially in culturally conservative populations. This study aimed to assess the relationship between newly diagnosed thyroid dysfunction and sexual function among married, premenopausal women in Basrah, Iraq, using the Arabic version of the Female Sexual Function Index (FSFI). Out of 673 women aged 20–48 years presenting with sexual complaints, 229 with clinically confirmed FSD were enrolled. Of these, 42 were newly diagnosed with thyroid dysfunction, either overt or subclinical, autoimmune or non-autoimmune, and served as the case group. In contrast, 187 women with normal thyroid function served as controls. Hormonal profiling included Thyroid- Stimulating Hormone (TSH), Free Thyroxine (FT4), total testosterone (TT), Sex Hormone-Binding Globulin (SHBG), Calculated Free Testosterone (cFT), Estradiol (E2), and Prolactin (PRL). FSFI domain scores and hormonal parameters were compared across groups and subgroups. Subclinical and overt thyroid dysfunction were identified in 8.3% and 10.04% of the cohort, respectively. FSFI scores were significantly low across all domains in both groups. Although the orgasm domain (p=0.043) and total FSFI score (p=0.020) showed statistical significance, the overall clinical impact was limited due to the uniformly low scores. Hormonal levels, including PRL, TT, SHBG, cFT, and E2, did not differ significantly between groups, except for higher E2 levels among women with autoimmune thyroid dysfunction (p=0.026). No significant differences in FSFI scores were observed between autoimmune and non-autoimmune groups, or between autoimmune hypothyroidism and autoimmune hyperthyroidism. These findings suggest that thyroid dysfunction, whether overt, subclinical, or autoimmune, does not appear to be a major determinant of FSD in this population. The results support a multifactorial origin of FSD and underscore the need for culturally sensitive, interdisciplinary approaches to better understand and manage sexual health concerns among women in conservative societies.


  • Open Access

    Optimizing hormone replacement therapy for postmenopausal women with type 2 diabetes: a review

    by Butheinah A. Al-Sharafi, Samih A. Odhaib

    Hormone replacement therapy (HRT) is essential for alleviating menopausal symptoms and mitigating complications linked to type 2 diabetes mellitus (T2DM) in postmenopausal women. Studies indicate that HRT may contribute to better glycemic control, improved lipid metabolism, and enhanced kidney function, which could help lower the risk of diabetes-related complications. Early initiation of HRT near menopause has shown cognitive and metabolic benefits, while transdermal estrogen is preferred for women with cardiovascular risk due to its safer profile. However, HRT is associated with risks, including thromboembolic events and increased risks of breast and endometrial cancers, necessitating individualized evaluations. Despite its potential, significant gaps remain regarding HRT’s long-term safety and efficacy, its interaction with modern diabetes therapies, and its impact on diverse populations. The optimization of estrogen replacement therapy (ERT) strategies requires further exploration, particularly regarding patient screening, individualized treatment regimens, and personalization of care based on risk factors such as metabolic status, cardiovascular health, and diabetes severity. Current evidence supports the cautious use of HRT in strictly screened postmenopausal women with T2DM, adhering to key principles including early intervention (within 10 years of menopause), low-dose and short-duration therapy (usually < 5 years), and integration of lifestyle interventions (e.g., diet, exercise). Future research should focus on defining clear screening criteria, optimizing treatment regimens, and personalizing ERT to maximize benefits while mitigating risks. This review examines the benefits, risks, and optimization strategies of HRT in postmenopausal women with T2DM. It focuses on its metabolic, cardiovascular, cognitive, and renal effects and emphasizes personalized treatment approaches.

  • Open Access

    Whole Pancreas and Islet Cell Transplantation for Patients with Type 1 Diabetes Mellitus: A Mini-Review and Middle East–North Africa Experience

    by Samih Abed Odhaib, Adel G. Mohammed, Hinde Iraqi

    Pancreas and islet cell transplantations (ICT) have significantly advanced the management of type 1 diabetes mellitus, offering viable alternatives for patients with severe glycemic instability or end-stage renal disease. Pancreas transplantation, particularly in the form of simultaneous pancreas–kidney transplantation, provides sustained glycemic control, reduces diabetes-related complications, and enhances quality of life. ICT, a less invasive alternative, effectively stabilizes blood glucose levels and minimizes hypoglycemic episodes but offers lower insulin independence rates. In the Middle East and North Africa (MENA) region, pancreas and islet transplantation programs have been gradually evolving, with notable progress in countries such as Iran and Saudi Arabia. However, challenges such as limited donor availability, technical complexities, and cultural barriers hinder their widespread implementation. The need for public awareness, healthcare infrastructure development, and international collaborations is critical for scaling these life-changing therapies across the region. This review examines the indications, modalities, and outcomes of pancreas and ICT globally, with a particular focus on the progress and challenges within the MENA region. It highlights advancements in surgical techniques, immunosuppressive regimens, and donor organ preservation that have improved transplantation outcomes over time. Furthermore, the review underscores the importance of implementation of tailored strategies to overcome regional barriers and expand access to these transformative therapies, offering valuable insights into the future directions of diabetes management through transplantation.


  • WITHDRAWN: Whole Pancreas and Islet Cells Transplantation for Patients with Type 1 Diabetes Mellitus: A Mini-Review and Middle East-North Africa Experience

    by Samih Abed Odhaib, Adel Gassab Mohammed, Hinde Iraqi

    Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has beenwithdrawn from the journal "Current Diabetes Review".Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.phpBENTHAM SCIENCE DISCLAIMER:It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneouslysubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewheremust be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submittingthe article for publication the authors agree that the publishers have the legal right to take appropriate action against theauthors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyrightof their article is transferred to the publishers if and when the article is accepted for publication.


  • Open Access

    Thyroid Function Screening among First- and Second-Degree Healthy Asymptomatic Relatives of Patients with Hashimoto’s Thyroiditis

    by Samih Abed Odhaib, Miaad Jassim Mohammed, Mahmood Thamer Altemimi, Abbas Ali Mansour

    Objective:: Assessment of thyroid dysfunction among relatives of patients diagnosed with Hashimoto’s thyroiditis is controversial due to the lack of evidence. Screening and prediction of thyroid dysfunction among first- and second-degree relatives (FDRs and SDRs) of patients were diagnosed with Hashimoto’s thyroiditis. Materials and Methods:: Three hundred and forty-six asymptomatic relatives of 97 patients diagnosed with Hashimoto’s thyroiditis were enrolled in mixed cross-sectional and prospective assessments for thyroid dysfunction over more than two years (September 2018-December 2020). Both FDR and SDR were evaluated by thyrotropin (TSH) and thyroid ultrasound at enrollment. Individuals with abnormal TSH were thoroughly evaluated biochemically and were subsequently classified as euthyroid, subclinical, and overt thyroid dysfunctional. The future reversion of enrolled individuals with normal and subclinical thyroid function to overt dysfunction was predicted by using the Thyroid Event Amsterdam (THEA) score. Results:: Three-quarters of the participants were non-smoking married women. Thyroid dysfunction was diagnosed among 43% of the participants (n=150), of whom two-thirds (74%) were having overt dysfunction (n=111). Neither the demographic elements nor the initial thyroid function could predict the future thyroid function among those participants. Two out of ten (16%) were having autoimmune thyroid disease (AITD) as part of familial clustering (n=56). Four participants with subclinical hypothyroidism were treated accordingly due to their high THEA score despite the global lower THEA score (5.00±0.44). Conclusion:: Screening of asymptomatic relatives of patients diagnosed with Hashimoto's thyroiditis could help identify the familial background of thyroid diseases in 43% of FDRs and SDRs. One-third may have an underlying autoimmune basis.

  • Open Access

    Effect of dulaglutide injection on weight beyond glycemic control: real-world observational study

    by Adel G. Mohammed, Samih A. Odhaib

    Dulaglutide is an effective Glucagon-like Peptide-1 (GLP-1) Receptor Agonist (RA) in optimizing weight and glycemic control in obese patients with Type 2 Diabetes Mellitus (T2DM). The study's objective was the real-world evaluation of the metabolic effect of Dulaglutide on weight and glycemic control in patients with T2DM from Southern Iraq. This study is a six-month observational prospective longitudinal evaluation of 185 obese individuals with T2DM. They were initiated on Dulaglutide as an add-on drug with Oral Antidiabetic (OAD) or insulin therapy. General characteristics of the patients, glycated hemoglobin (HbA1c), blood glucose, lipid profile, and side effects profile were evaluated at the enrollment and the end of the study. The enrolled 185 obese patients with T2DM, had a T2DM duration (2 -14 years) and initial HbA1c range (6 - 19.5%), with different treatment modalities, including insulin, OADs, or both. The study showed a significant reduction in weight, HbA1c, and serum cholesterol, with minimal hypoglycemic events in 5% of patients (n=9). The gastrointestinal side effects were mild to moderate and self-limited in >96% of patients (n=178), while they were so severe in 4% (n=7) and caused discontinuation of Dulaglutide. Therefore, the insulin regimen was either stopped (n=28), changed (n=7), or reduced (n=9). No change on oral medications was performed in 141 patients. In conclusion, Dulaglutide 1.5 mg administered once a week significantly reduced the weight, HbA1c, Self-Monitoring of Blood Glucose (SMBG), and cholesterol levels with minimal hypoglycemic risk.

  • Open Access

    Glycemic effects of Catha edulis

    by Samih Abed Odhaib, Butheinah A. Al-Sharafi, Abbas Ali Mansour

    More than 20 million people in the East African horn and the southern Arabian Peninsula chew khat (Catha edulis) on a daily basis. The glycemic effect of khat chewing, regardless of diabetes status, is still being debated. Using studies from countries where chewing khat is common, we attempted to discuss the potential glycemic effects of Catha edulis in humans and some animal models. This review included a thorough search in PubMed and the Cochrane Library using PRISMA guidelines, with words like (Khat) and (Qat) serving as query indicators for (diabetes) and (glucose), with no language or species restrictions. Khat is chewed for its stimulating and enjoyable properties. Despite a relatively small number of studies on khat’s glycemic effect, the debate continues. Many studies have linked the glycemic effect of khat leaves to their freshness and the duration of the stimulant effect. Although only in animal models, khat’s destructive effect on pancreatic -cells could cause some dysglycemic effects. The cathinone cannot be blamed for the glycemic effect.

  • Open Access

    Flutamide-induced hepatotoxicity: A case report

    by Omer M. Kassid, Samih A. Odhaib, Mahmood Thamer Altemimi

    Flutamide is a non-steroidal anti-androgen drug effective in the management of prostatic carcinoma. The drug appears to be well tolerated with mild gastrointestinal adverse events and gynecomastia. Flutamide-induced hepatotoxicity may range from minor elevation in liver enzymes to hepatic failure. Here, we tried to discuss the possibility of hepatotoxicity induced by flutamide as antiandrogen therapy in a patient with prostatic adenocarcinoma. Here we present a 75-year-old man who commenced flutamide as a postoperative anti-androgen for prostatic adenocarcinoma for two months. He had markedly elevated levels of liver enzymes due to acute liver failure and subsequent multi-organ failure. The patient died after the failure of the resuscitation measures. The temporal relationship between the flutamide initiation and the emergence of hepatotoxicity is not clear, with a possible latency of 12-16 weeks. Careful monitoring of liver function test during flutamide therapy is essential to prevent serious hepatotoxicity.